Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.
about
Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformationsInhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1.PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathwaysTargeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.Angiopoietin-1 and myeloma-induced angiogenesis.Angiogenic switch in multiple myeloma.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoDevelopment of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimizationMolecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Gan-Lu-Yin Inhibits Proliferation and Migration of Murine WEHI-3 Leukemia Cells and Tumor Growth in BALB/C Allograft Tumor Model.Estrogen receptor-alpha overexpression suppresses 17beta-estradiol-mediated vascular endothelial growth factor expression and activation of survival kinasesPI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells.Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.Transcription factors regulate GPR91-mediated expression of VEGF in hypoxia-induced retinopathy.Biliverdin reductase: a target for cancer therapy?Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance.An Evidence-Based Approach to Myeloma Bone Disease.G protein-coupled receptor 91 signaling in diabetic retinopathy and hypoxic retinal diseases.Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.Lipid peroxidation-induced VEGF expression in the skin of KKAy obese mice.Angiogenesis and multiple myeloma.Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy.Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.Activation of the complement system in an osteosarcoma cell line promotes angiogenesis through enhanced production of growth factors.Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
P2860
Q24314844-6991BF31-F214-4D3D-9ACF-A5628248F372Q31028788-A937F560-3EB8-41D5-9772-BBD7C491A422Q33947892-02076A77-6A3D-4F5F-9B5F-881FC81A3BB6Q34124937-79D2AA64-C55B-4B9B-954A-31D787C0F840Q34309479-EA1ECD15-4DDD-440F-B129-8DF949FC2368Q35989478-E13B1DF3-0E7E-45DC-814F-83D04DCB2E5AQ35994897-15790883-4AC8-4A86-8E9D-7710CA09D82CQ36069477-B2E66F83-B858-49BD-8C45-1D6D5820644CQ36162685-996FE772-0FDF-494E-90D7-20E5EC1DA32DQ36189476-94F0FEF5-9957-4194-A4EB-7290EB2DBF9CQ36414422-95FCB162-58BA-4F44-AC60-75508CF6328AQ36731075-862D3262-8A3A-4DF9-8533-68576D06A37BQ36796731-8B6B9609-4EB7-4B9E-95F1-A115B7E78BD2Q37016007-BC4D07B2-654C-4F4F-963A-5F681550A68BQ37061808-D2EF63DE-4C65-4B42-A260-158D9DC0809EQ37385705-E484A0F7-CEA8-4839-8481-973C7BE39ACDQ37736685-A704AAF3-7F9F-491F-BA06-B9E01575A5CFQ38531952-71D462B9-BCEE-4624-8F0E-28AFE00A56FBQ38868587-CA8AF98F-8D8F-4B5F-B4ED-D524561E436BQ39153978-4D428A0A-9481-4B7D-8FA2-4D86006B695EQ39327108-04997B21-BE5E-499A-9BA4-4DAF42AF2171Q39584006-257CF413-BDE6-48B5-A1C6-3091612AC707Q39585247-FE41DE29-8CE5-41FC-9557-CF266B77442BQ39696428-650EC2A9-367C-4B84-A47F-86855B9D3CA2Q39771144-3D176A58-266B-454B-9947-25FADD106BB5Q40125230-CAD082BA-0693-4D1F-AE29-E4E38C2F9EF4Q40406392-1D8E00A8-F1BA-46C2-8D47-074C0D03317EQ42511343-EDE81EFE-688D-4134-AD58-E0F2347537E9Q48349526-838B3FEA-FDD3-45E5-B207-5A5FEA90F8E2Q54496082-B29C5542-84EB-4E15-8FAD-72BFED3ACD1AQ55013345-72B93B0A-A508-4667-9E81-7A58C3739A63Q57044361-58665507-716D-4DC6-87E3-A6F1FC6D708D
P2860
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@en
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@nl
type
label
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@en
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@nl
prefLabel
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@en
Downmodulation of ERK protein ...... myeloma-induced angiogenesis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Downmodulation of ERK protein ...... d myeloma-induced angiogenesis
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403269
P577
2004-03-01T00:00:00Z
P5875
P6179
1032115202